NEW YORK (GenomeWeb News) – Axela today announced a development deal to integrate Thermal Gradient's rapid PCR technology into Axela's Flow-Thru Chip automated workflow.
Initially, Thermal Gradient's technology will added to Axela's patent pending approach for capturing and quantifying targeted nucleic acids. The workflow is now optimized for formalin-fixed, paraffin-embedded tissue and is designed for use with other specimens, including other biopsy samples, blood, and isolated cells.
Axela's Flow-Thru Chip platform is meant for researchers who need technology to address the gap between multiplexed PCR and high density DNA/RNA arrays, the Toronto-based firm said.
"Our technology enables us to design inexpensive devices that perform PCR in just a few minutes," Robert Juncosa, CEO of Rochester, NY-based Thermal Gradient, said in a statement. "It is our business model to adapt our PCR and other sample preparation capabilities to a partner's application. The integration of our technology with Axela's Flow-Thru Chip rapid hybridization and detection capabilities will provide a powerful automated solution for the broad markets that benefit from higher multiplex analysis."
Financial and other terms of the deal were not disclosed.